Oral coadministration of Am80 (an RAR-α/β agonist) and HX630 (an RXR agonist) reduced the level of insoluble Aβ peptide in the brain by promoting the differentiation of IL-4-responsive M2-like microglia and increasing their activity for the clearance of oligomeric Aβ peptides in an experimental model of AD. Here, RARA is linked to Alzheimer disease.